Business Context and Reporting Period
This Form 8-K, dated July 21, 2022, reports a material definitive agreement between Silverback Therapeutics, Inc. ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS"). ARS is a biopharmaceutical company developing neffy, a needle-free epinephrine nasal spray for Type I allergic reactions. The filing details a merger agreement where ARS will become a wholly-owned subsidiary of Silverback.
Key Financial Metrics and Transaction Terms
- Ownership Structure: Post-merger, ARS equity holders are expected to own approximately 63% of the combined company, while Silverback equity holders will own approximately 37% on a fully-diluted basis.
- Cash Conditions: The transaction assumes Silverback's net cash at closing is $240 million. Closing conditions require net cash to be between $210 million and $255 million; excess cash above $255 million may be returned via dividend.
- Termination Fees: A $6 million fee is payable by either party under certain termination scenarios. A $10 million fee is payable by Silverback if it terminates to pursue a superior transaction.
- Expense Reimbursement: Silverback agreed to reimburse ARS up to $1.5 million in expenses if the merger fails due to lack of stockholder approval.
- Workforce Reduction Costs: Silverback estimates $13 million in cash severance charges and $2 million in non-cash equity charges in Q3 and Q4 2022 related to a 73% workforce reduction.
Material Changes and Operational Impact
Upon signing the agreement, Silverback committed to reducing its workforce by approximately 73% by September 2, 2022, with the remaining 27% to be reduced at transaction close. This action is intended to preserve cash resources. Additionally, Silverback amended compensatory arrangements for named executive officers, extending post-termination stock option exercise periods to 12 months and triggering Change in Control severance benefits.
Guidance, Outlook, and Risks
- Management: Rich Lowenthal (ARS) will serve as CEO of the combined company. The board will consist of 10 directors: 7 designated by ARS and 3 by Silverback.
- Closing Conditions: The merger is subject to stockholder approvals, regulatory clearances (including HSR Act), and the submission of ARS's New Drug Application (NDA) for neffy to the FDA.
- Support Agreements: Support agreements representing 83% of ARS stock and 31% of Silverback stock have been executed to vote in favor of the merger.
- Lock-Up Agreements: Key insiders from both companies have agreed to lock-up restrictions on share transfers for 180 days post-closing.
- Risks: Risks include failure to obtain stockholder approval, regulatory delays, failure to submit the NDA, and the potential for the transaction to be terminated.
Investor Verification Checklist
- Verify the final net cash position of Silverback at closing to confirm it falls within the $210 million to $255 million range required for the deal to close without adjustment.
- Monitor the status of ARS's New Drug Application (NDA) submission for neffy, a mandatory closing condition.
- Review the upcoming proxy statement for details on the exchange ratio and voting procedures.
- Confirm the actual severance costs incurred against the estimated $13 million cash and $2 million non-cash charges.
- Track the approval process for the issuance of Silverback shares representing more than 20% of outstanding stock under Nasdaq rules.